148 related articles for article (PubMed ID: 36994539)
1. Influencing factors of efficacy and long-term use of amrubicin in patients with small cell lung cancer.
Takahara Y; Tanaka T; Ishige Y; Shionoya I; Yamamura K; Sakuma T; Nishiki K; Nakase K; Nojiri M; Kato R; Shinomiya S; Oikawa T; Mizuno S
Thorac Cancer; 2023 May; 14(14):1286-1293. PubMed ID: 36994539
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01).
Uematsu S; Kitazono S; Tanaka H; Saito R; Kawashima Y; Ohyanagi F; Tozuka T; Ryosuke T; Sakatani T; Horiike A; Yoshizawa T; Saiki M; Tambo Y; Koyama J; Kanazu M; Kudo K; Tsuchiya-Kawano Y; Yanagitani N; Nishio M
Thorac Cancer; 2023 Jan; 14(2):168-176. PubMed ID: 36408699
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of amrubicin third-line chemotherapy in patients with relapsed extensive-disease small-cell lung cancer: A retrospective and historical study in a single institute.
Sonehara K; Tateishi K; Fukushima T; Komatsu M; Yamamoto H; Koizumi T; Hanaoka M
Thorac Cancer; 2019 Sep; 10(9):1805-1811. PubMed ID: 31350820
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.
Okuma HS; Horinouchi H; Kitahara S; Asao T; Sunami K; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Ohe Y
Clin Lung Cancer; 2017 Mar; 18(2):234-240.e2. PubMed ID: 27867001
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer.
Mitsuoka S; Kudoh S; Kimura T; Yoshimura N; Tanaka H; Suzumura T; Umekawa K; Nagata M; Ueda T; Hirata K
Osaka City Med J; 2011 Dec; 57(2):59-66. PubMed ID: 22443079
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second-line chemotherapy in patients with small cell lung cancer.
Sekikawa M; Murakami H; Morita M; Doshita K; Miura K; Kodama H; Morikawa N; Iida Y; Mamesaya N; Kobayashi H; Ko R; Wakuda K; Ono A; Kenmotsu H; Naito T; Chiba H; Takahashi T
Thorac Cancer; 2023 Dec; 14(35):3475-3482. PubMed ID: 37873674
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
Igawa S; Shirasawa M; Fukui T; Nishinarita N; Sone H; Ozawa T; Sugita K; Okuma Y; Kurahayashi S; Ono T; Sugimoto A; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
Oncology; 2018; 94(4):207-214. PubMed ID: 29393275
[TBL] [Abstract][Full Text] [Related]
8. Amrubicin monotherapy for elderly patients with relapsed extensive-disease small-cell lung cancer: A retrospective study.
Sone H; Igawa S; Kasajima M; Ishihara M; Hiyoshi Y; Hosotani S; Ohe S; Ito H; Kaizuka N; Manaka H; Fukui T; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
Thorac Cancer; 2018 Oct; 9(10):1279-1284. PubMed ID: 30126051
[TBL] [Abstract][Full Text] [Related]
9. Lower optimal dose of amrubicin for relapsed small-cell lung cancer: a retrospective study.
Nakamichi S; Kubota K; Zou F; Hayashi A; Takano N; Onda N; Matsumoto M; Miyanaga A; Noro R; Seike M
Int J Clin Oncol; 2023 Jul; 28(7):872-879. PubMed ID: 37171692
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802.
Kawashima Y; Inoue A; Sugawara S; Oizumi S; Maemondo M; Okudera K; Suzuki T; Usui K; Harada M; Morikawa N; Hasegawa Y; Saito R; Ishimoto O; Sakakibara T; Asahina H; Nukiwa T
Respir Investig; 2014 May; 52(3):190-4. PubMed ID: 24853020
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients.
Imai H; Sugiyama T; Tamura T; Minemura H; Kaira K; Kanazawa K; Yokouchi H; Kasai T; Kaburagi T; Minato K;
Cancer Chemother Pharmacol; 2017 Sep; 80(3):615-622. PubMed ID: 28761968
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401).
Tanaka H; Hasegawa Y; Fujita Y; Nakamura A; Kikuchi E; Kawai Y; Harada T; Watanabe N; Yokouchi H; Usui K; Saito R; Watanabe H; Masuda T; Fukuhara T; Kudo K; Honda R; Oizimi S; Maemondo M; Inoue A; Morikawa N
Thorac Cancer; 2021 Jul; 12(14):2113-2121. PubMed ID: 34076966
[TBL] [Abstract][Full Text] [Related]
13. Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance status.
Igawa S; Shirasawa M; Ozawa T; Nishinarita N; Okuma Y; Ono T; Sugimoto A; Kurahayashi S; Sugita K; Sone H; Fukui T; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
Thorac Cancer; 2018 Aug; 9(8):967-973. PubMed ID: 29870153
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
Inoue A; Sugawara S; Maemondo M; Mori Y; Oizumi S; Harada M; Taima K; Morikawa N; Ishida T; Kinoshita I; Watanabe H; Suzuki T; Nakagawa T; Saito R; Nukiwa T
Lung Cancer; 2015 Jul; 89(1):61-5. PubMed ID: 26004087
[TBL] [Abstract][Full Text] [Related]
15. Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies: HOG LUN 07-130.
Jalal SI; Hanna N; Zon R; Masters GA; Borghaei H; Koneru K; Badve S; Prasad N; Somaiah N; Wu J; Yu Z; Einhorn L
Am J Clin Oncol; 2017 Aug; 40(4):329-335. PubMed ID: 25503432
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.
Wakuda K; Kenmotsu H; Naito T; Akamatsu H; Ono A; Shukuya T; Nakamura Y; Tsuya A; Murakami H; Takahashi T; Endo M; Nakajima T; Yamamoto N
Am J Clin Oncol; 2015 Feb; 38(1):28-32. PubMed ID: 23388567
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of small-cell lung cancer since the introduction of amrubicin.
Suzuki H; Hirashima T; Kobayashi M; Sasada S; Okamoto N; Tamiya M; Matsuura Y; Morishita N; Uehara N; Matsui K; Kawase I
Med Oncol; 2011 Dec; 28(4):1430-5. PubMed ID: 20632217
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer.
Imai H; Nagai Y; Minemura H; Tsuda T; Yamada Y; Wasamoto S; Kishikawa T; Shiono A; Shiihara J; Yamaguchi O; Mouri A; Kaira K; Kanazawa K; Taniguchi H; Minato K; Kagamu H
Invest New Drugs; 2022 Oct; 40(5):1066-1079. PubMed ID: 35749041
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Second-line Chemotherapy in Patients With Sensitive Relapsed Small-cell Lung Cancer.
Wakuda K; Miyawaki T; Miyawaki E; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Nakashima K; Ono A; Kenmotsu H; Naito T; Murakami H; Mori K; Endo M; Takahashi T
In Vivo; 2019; 33(6):2229-2234. PubMed ID: 31662561
[TBL] [Abstract][Full Text] [Related]
20. Lactate dehydrogenase and body mass index are prognostic factors in patients with recurrent small cell lung cancer receiving amrubicin.
Inomata M; Hayashi R; Tokui K; Taka C; Okazawa S; Kambara K; Ichikawa T; Yamada T; Miwa T; Kashii T; Matsui S; Tobe K
Tumori; 2016 Dec; 102(6):606-609. PubMed ID: 26429641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
